Do you want to read an article? Please log in or register.
Efficacy and safety of elotuzumab for the treatment of multiple myeloma
Multiple Myeloma (MM)
Related content
Multiple Myeloma (MM)
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison
Oncologist.
Van Sanden S, Ito T, Diels J, Vogel M, Belch A, Oriol A
doi: 10.1634/
Multiple Myeloma (MM)
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
Blood Cancer J
Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ
doi: 10.1038/s41408-021-00432-4
Multiple Myeloma (MM)
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Leukemia.
Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H
doi: 10.1038/leu.2017.122.
COMMENTED
Multiple Myeloma (MM)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1016/S2352-3026(20)30070-3.
Multiple Myeloma (MM)
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
Int J Mol Sci.
Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S
doi: 10.3390/ijms19072087.
Multiple Myeloma (MM)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Lancet Haematol.
Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators.
doi: 10.1016/
Multiple Myeloma (MM)
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Drugs.
Lamb YN
doi: 10.1007/s40265-018-0969-4.
Multiple Myeloma (MM)
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Ther Adv Hematol.
Magen H, Muchtar E
doi: 10.1177/
Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
Int J Clin Pharmacol Ther.
Hu B, Zhou Q, Wu T, Zhuang L, Yi L, Cao J, Yang X, Wang J
doi: 10.5414/CP202714